Cite
norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study
MLA
Traussnigg, Stefan, et al. NorUrsodeoxycholic Acid (NorUDCA) Improves Non-Alcoholic Fatty Liver Disease (NAFLD): Results from a Randomized Placebo-Controlled, Double-Blind Phase IIa Study. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1201322217&authtype=sso&custid=ns315887.
APA
Traussnigg, S., Schattenberg, J. M., Demir, M., Wiegand, J., Geier, A., Teuber, G., Hofmann, W. P., Kremer, A. E., Spreda, F., Kluwe, J., Petersen, J., Boettler, T., Halilbasic, E., Greinwald, R., Proels, M., Manns, M. P., Fickert, P., & Trauner, M. H. (2017). norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study.
Chicago
Traussnigg, Stefan, Jorn M. Schattenberg, Muenevver Demir, Johannes Wiegand, Andreas Geier, Gerlinde Teuber, Wolf Peter Hofmann, et al. 2017. “NorUrsodeoxycholic Acid (NorUDCA) Improves Non-Alcoholic Fatty Liver Disease (NAFLD): Results from a Randomized Placebo-Controlled, Double-Blind Phase IIa Study.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1201322217&authtype=sso&custid=ns315887.